Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity.
AffiliationDepartment of Surgery, University Hospital of South Manchester, West Didsbury, UK.
MetadataShow full item record
AbstractAnti-oestrogen therapy is being used in an attempt to prevent breast cancer but no intermediate end points of the effect of tamoxifen on the normal breast are available. Therefore, the purpose of this study was to develop a physiological measure of oestrogen action on the breast. We measured oestrogen-stimulated and -inhibited proteins in breast secretions from women on and off anti-oestrogen therapy. Two oestrogen-stimulated proteins (pS2 and cathepsin D) and oestrogen-inhibited proteins (CP15, gross cystic disease fluid protein 15; Apo,: apolipoprotein D) were measured. Premenopausal women had significantly higher pS2 and cathepsin D in association with lower Apo D and CP15 secretion levels compared to post-menopausal women. Sequential nipple aspirates from women treated with the luteinizing hormone releasing hormone agonist goserelin (n = 9), tamoxifen (n = 9) and hormone replacement therapy (HRT) (n = 26) were measured. Following treatment with goserelin, median nipple secretion levels of pS2 fell (P < 0.02) and Apo D and CP15 rose significantly (P < 0.03 and P < 0.05 respectively). Similar changes were seen on tamoxifen therapy but not in untreated control women. Treatment with HRT resulted in a rise of pS2 (P < 0.001) and a fall in Apo D (P < 0.05). Measurement of pS2 and Apo D in nipple aspirates may prove useful intermediate end point of breast responsiveness to anti-oestrogens.
CitationHormonally-regulated proteins in breast secretions are markers of target organ sensitivity. 2000, 82 (2):354-60 Br. J. Cancer
JournalBritish Journal of Cancer
- Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
- Authors: Pujol P, Daurès JP, Brouillet JP, Maudelonde T, Rochefort H, Grenier J
- Issue date: 1999 Feb
- Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
- Authors: Dittadi R, Biganzoli E, Boracchi P, Salbe C, Mione R, Gatti C, Gion M
- Issue date: 1998 Jan-Mar
- Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
- Authors: Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T
- Issue date: 2011 Aug
- Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
- Authors: Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE
- Issue date: 2004 Sep 15
- Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study.
- Authors: Eskelinen M, Kataja V, Hämäläinen E, Kosma VM
- Issue date: 1999 Jul-Aug